Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07643012 · ClinicalTrials.gov registry record · NA
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
A NA study, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT07643012 is a NA study that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants.
The verdict
NCT07643012, a NA study, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
Interventions
- RADIATION MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-06-09 |
| Est. Completion | 2029-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07643012
The ClinicalTrials.gov registry entry for NCT07643012 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) is the first listed.
NCT07643012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07643012 about?
NCT07643012 is a clinical study titled "Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer". To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
What is the current status of trial NCT07643012?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2026-06-09. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07643012?
The interventions under investigation include: MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT) (RADIATION).
Who is sponsoring clinical trial NCT07643012?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.